NEWS RELEASE

Schrödinger and Tri-Institutional Therapeutics Discovery Institute Renew Agreement to Provide Drug Discovery Software to Tri-Institutional Researchers

4/12/2018

biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Schrödinger's investors include David E. Shaw and Bill Gates. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrödinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schrödinger has over 300 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit **www.schrodinger.com**.

Schrödinger Contacts:
Investors:
Christina Tartaglia
Stern Investor Relations, Inc.
212-362-1200
christina@sternir.com

Media:
Shi-Yi Liu, Ph.D.
503-299-1150 x108
shi-yi.liu@schrodinger.com